Yu-Wan Yang

Yu-Wan Yang

Auto-generated profile, based on publicly available information

Yu-Wan Yang

Department of Neurology, China Medical University Hospital, Taichung, 40447, Taiwan; School of Medicine, College of Medicine, China Medical University, Taichung, 40402, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
WYWei-Yang Yu
Wei-Yang Yu
TSTing-Hsuan Sun
Ting-Hsuan Sun
KHKai-Cheng Hsu
Kai-Cheng Hsu
CWChia-Chun Wang
Chia-Chun Wang
SCShang-Yu Chien
Shang-Yu Chien
YYYu-Wan Yang
Yu-Wan Yang

10 September 2021 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
CCChiung-Chih Chang
Chiung-Chih Chang
LCLung Chan
Lung Chan
HCHsi-Hsien Chou
Hsi-Hsien Chou
YYYu-Wan Yang
Yu-Wan Yang
TCTa-Fu Chen
Ta-Fu Chen
CHChaur-Jong Hu
Chaur-Jong Hu
Introduction The current study aimed to provide data on the effectiveness of the 10 cm2 rivastigmine patch in patients with Alzheimer’s disease (AD) in a real-world setting in Taiwan. Methods This was a 48-week, single-arm, open-label, observational, and post-marketing study conducted across seven centers in Taiwan between May 5, 2016 and July 10, 2017. Eligible patients (aged 55–95 years) treated with the 10 cm2rivastigmine patch were enrolled based on physicians’ judgment and according to the Taiwan reimbursement criteria of the drug. Data were prospectively collected at Week 0 (baseline), Week 24, and Week 48. The primary endpoint was the change in the cognitive assessment screening instrument (CASI) scores at Week 48 versus baseline. The changes from baseline in clinical dementia rating (CDR), mini-mental state examination (MMSE), and neuropsychiatric inventory (NPI) scores were evaluated, as were treatment persistence and the safety profile. Results Of the 285 eligible patients [full analysis set (FAS)], 216 (75.8%) completed the study protocol while 180 (63.2%) persisted on the 10 cm2 rivastigmine patch for the full 48 weeks. At baseline, 89.8% of patients had a CDR score of 0.5 or 1, while the change in CDR score at Week 48 was not significant. In the FAS, both the CASI and MMSE scores had numerical improvement at Week 24 but declined by 2.1 and 0.4 points, respectively, at Week 48 (p = 0.005 and p = 0.022). The increment in NPI scores was not significant. The most common drug-related adverse events (AEs) were pruritus (11.2%), nausea (3.5%), rash (3.2%), and vomiting (2.8%). Conclusions The use of the 10 cm2 rivastigmine patch in the mild stage of AD maintained cognitive function at Week 24 and neuropsychiatric function at Week 48. The treatment persistency and safety profile support the clinical tolerability of the rivastigmine patch in the management of mild-to-moderate AD in Taiwan.